Comorbid anxiety and depression is a fairly common phenomena and is often associated with other health conditions like diabetes, stroke, Alzheimer’s, Parkinson’s, epilepsy, OCD and schizophrenia.

The treatment of comorbid anxiety and depression necessitates specific psychopharmacological adjustments as compared to treating either condition alone. Serotonin reuptake inhibitors are considered first-line treatment in uncomplicated depression comorbid with a spectrum of anxiety disorders. Short-acting benzodiazepines (BZDs) are an important “bridging strategy” to address an acute anxiety component.

STALOSANT PLUS contains Escitalopram as well as Clonazepam which provides a comprehensive and rational treatment approach towards comorbid anxiety and depression and also improves treatment outcomes in other associated health conditions.